Brind.

Takeda's drug, FRUZAQLA™, received public reimbursement in Quebec after Health Canada granted market authorization.

1 report, 1 independent Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Takeda's drug, FRUZAQLA™, received public reimbursement in Quebec after Health Canada granted market authorization.

Who's involved

What this event is mainly about
Quebec City

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • CNW GroupTakeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC) TORONTO, Aug. 28, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to ann